Development and characterization of a long-acting nanoformulated abacavir prodrug - Wikidata - wikimedia - TriplyDB

Development and characterization of a long-acting nanoformulated abacavir prodrug

Development and characterization of a long-acting nanoformulated abacavir prodrug

http://www.wikidata.org/entity/Q41280373

about

Long-acting slow effective release antiretroviral therapy.Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging.Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution.Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques.Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.Creation of a long-acting nanoformulated dolutegravir.Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LC-MS/MS.Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals.

P2860

Q36262152-8864B273-CE80-4D53-8F7C-41CC7F3D958C Q37639081-44CDB1E1-2050-4540-B650-7ACC6525FF1B Q37692595-4E7F8216-0F43-4F85-B7E8-0035573D7EE0 Q38787356-BED8E803-9021-4124-8911-6501730475D9 Q38992323-9F8F371A-B429-4E6C-8E8B-4E4025EB4A19 Q47095093-ACEA046C-12AF-4433-B35D-B4D5F54A021F Q47142890-F9DD4CA0-B6CA-4044-82C9-4C3C7A1E2E2E Q47603651-EFD184C7-352C-4E28-9F8B-D34014571DEA Q50051618-08DACB68-2AA9-42A6-8DC7-AE7137DF0862 Q52666512-1B312127-177A-42B4-BD60-9D7C37DE019B Q54253541-AF31896D-0456-4091-8272-0765091B36FB

P2860

Development and characterization of a long-acting nanoformulated abacavir prodrug

http://www.wikidata.org/entity/Q41280373

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Development and characterization of a long-acting nanoformulated abacavir prodrug

@en

type

label

Development and characterization of a long-acting nanoformulated abacavir prodrug

@en

prefLabel

Development and characterization of a long-acting nanoformulated abacavir prodrug

@en

P1433

Q41280373-83E24361-2F26-426A-AAAA-F7CC00ED92C1

P1476

Q41280373-2C9425D5-F6BD-4184-8A41-1A9A458397F4

P2093

Q41280373-2CBE3B79-800F-497F-931A-CB091E676644

Q41280373-451E7070-C223-4699-A8A1-6B33B152FBA1

Q41280373-8B439C7D-D52F-4A32-9DD6-53C7E7D5D86B

Q41280373-A1337BA0-8E60-40C1-B743-FA919388DA8E

Q41280373-B246E809-F80C-47FF-B9D2-5D9869E68D88

Q41280373-C7118BB9-0871-417B-9EB2-CC2559F2E528

Q41280373-D55F93D7-5178-4588-B5B7-F2178AFE2628

Q41280373-DC92789E-0665-494E-9129-4707AFB4CD2C

P2860

Q41280373-00DE2AB8-8991-459F-A16E-B5A82C0FE2F5

Q41280373-011E62C5-5567-4921-9707-7C9E6ED824F6

Q41280373-07617559-67D0-4EB9-AADE-9CAF53AE09D7

Q41280373-0884BA4A-9D89-4ED7-A2AB-5B1895A3DF67

Q41280373-0ABFAFEA-25F4-4439-BAC9-EEC00B1E392D

Q41280373-0B60300C-65D9-4739-8857-1288EF11D4F7

Q41280373-0B754E48-0DC3-475E-AACC-C8F39DF5B016

Q41280373-1664CF7D-0728-46B7-80ED-0D07904EB009

Q41280373-21D211EC-F209-43C9-A4B4-C49B8E93E859

Q41280373-28D375A9-783B-4B4B-AC91-36291FD0BD14

P304

Q41280373-340D3D78-A5B8-466C-A838-FEBDC393DEAB

P31

Q41280373-26FBE5BD-36E3-4A09-B86C-3740D785E314

P356

Q41280373-CB7C9E55-9B43-4495-B0A8-AC0CF752C53D

P433

Q41280373-9FC83D31-579D-4D00-ABD9-68DEEBE9F25B

P478

Q41280373-430BE452-4D22-4A8A-97E1-4D379DB0706C

P577

Q41280373-73EB248F-0CE4-4BF8-9844-C227058E7DC8

P698

Q41280373-538D371E-A3CE-4BDC-B425-A7348453A793

P932

Q41280373-E0B2A981-C7D7-44BD-9596-4CAE1DEE4685

P356

P1433

P1476

Development and characterization of a long-acting nanoformulated abacavir prodrug

@en

P2093

Benson Edagwa

http://www.w3.org/2001/XMLSchema#string

Dhirender Singh

http://www.w3.org/2001/XMLSchema#string

Diana Palandri

http://www.w3.org/2001/XMLSchema#string

Howard E Gendelman

http://www.w3.org/2001/XMLSchema#string

James Hilaire

http://www.w3.org/2001/XMLSchema#string

JoEllyn McMillan

http://www.w3.org/2001/XMLSchema#string

Nagsen Gautam

http://www.w3.org/2001/XMLSchema#string

Yazen Alnouti

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

Anti-HIV-1 nanotherapeutics: promises and challenges for the future

Macrophages recognize size and shape of their targets

The biology and enzymology of protein N-myristoylation

Improved Safety, Bioavailability and Pharmacokinetics of Zidovudine through Lactoferrin Nanoparticles during Oral Administration in Rats

Preexposure prophylaxis for HIV infection among African women

Combinatorial approaches to the prevention and treatment of HIV-1 infection

Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery.

NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.

P304

1913-1927

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/NNM-2016-0164

http://www.w3.org/2001/XMLSchema#string

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27456759

http://www.w3.org/2001/XMLSchema#string

P932

4996153

http://www.w3.org/2001/XMLSchema#string